Home » Stocks » FULC

Fulcrum Therapeutics, Inc. (FULC)

Stock Price: $10.40 USD -0.04 (-0.38%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $10.54 +0.14 (1.35%) May 12, 5:48 PM
Market Cap 341.18M
Revenue (ttm) 12.86M
Net Income (ttm) -69.37M
Shares Out 32.68M
EPS (ttm) -14.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $10.40
Previous Close $10.44
Change ($) -0.04
Change (%) -0.38%
Day's Open 10.46
Day's Range 10.26 - 10.72
Day's Volume 34,216
52-Week Range 7.01 - 22.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on track to re...

Other stocks mentioned: EVFM
3 hours ago - Benzinga

CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

12 hours ago - GlobeNewsWire

CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

5 days ago - GlobeNewsWire

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

– On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 –

6 days ago - GlobeNewsWire

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de...

1 week ago - GlobeNewsWire

Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de...

1 month ago - GlobeNewsWire

– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints –

1 month ago - GlobeNewsWire

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

2 months ago - Zacks Investment Research

– Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 –

2 months ago - GlobeNewsWire

– Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor –

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

2 months ago - GlobeNewsWire

Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world Theme of global unity highlights critical role of b...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

3 months ago - GlobeNewsWire

Owen Wallace to Transition to Scientific Advisory Board Owen Wallace to Transition to Scientific Advisory Board

3 months ago - GlobeNewsWire

Event will review the company's novel approach to inducing fetal hemoglobin

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

5 months ago - GlobeNewsWire

Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).

6 months ago - Zacks Investment Research

Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058 Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) --   Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d...

7 months ago - GlobeNewsWire

- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease

7 months ago - GlobeNewsWire

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) revealed late last week his firm upped its stake in Dave & Buster's Entertainment Inc.

Other stocks mentioned: PLAY
7 months ago - GuruFocus

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...

8 months ago - GlobeNewsWire

Fulcrum Therapeutics Inc. (FULC) CEO Robert Gould on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

– Conference call scheduled for 8:00 a.m. ET today –

9 months ago - GlobeNewsWire

Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expression

9 months ago - GlobeNewsWire

Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Other stocks mentioned: ARCT, AVRO, ETNB, ICPT
9 months ago - Zacks Investment Research

Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

9 months ago - Zacks Investment Research

Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression Collaboration will Combin...

9 months ago - GlobeNewsWire

Fulcrum stock gapped up Wednesday after the Food and Drug Administration gave it the go-ahead to begin a coronavirus treatment study. The drug is also in testing for muscular dystrophy.

10 months ago - Investors Business Daily

The U.S. Food and Drug Administration (FDA) has notified Fulcrum Therapeutics Inc.

10 months ago - 24/7 Wall Street

Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Fulcrum receives early notification from U.S. Food and Drug Administration (FDA) that study may proceed Fulcrum receives early notification from U.S. Food and Drug Administration (FDA) that study may pr...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC) today announced the closing of a $68.5 million private placement pursuant to a securities purchase agr...

11 months ago - GlobeNewsWire

Investigational New Drug (IND) application submitted; Company preparing to initiate Phase 3 trial

11 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).

11 months ago - Zacks Investment Research

Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Conference call scheduled for 8:00 a.m. ET today Conference call scheduled for 8:00 a.m. ET today

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...

1 year ago - GlobeNewsWire

– Losmapimod achieves target engagement in muscle –

1 year ago - GlobeNewsWire

Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed t... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2019
Stock Exchange
NASDAQ
Ticker Symbol
FULC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is 19.13, which is an increase of 83.94% from the latest price.

Price Target
$19.13
(83.94% upside)
Analyst Consensus: Buy